146 results about "Hyperinflammatory disorder" patented technology

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and OX40L in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and TSLP biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-OX40L antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or OX40L.

The present disclosure relates to a crystalline form of trans-4-[1-(3-Chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and its use as a therapeutic agent to treat inflammatory diseases.

The present disclosure relates to a crystalline form of trans-4-[1-(3-Chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and its use as a therapeutic agent to treat inflammatory diseases.

Provided herein are methods of treating or preventing a T-cell mediated inflammatory disease or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds to human PSGL-1 in combination with a Janus kinase (JAK) inhibitor. In some embodiments, the T-cell mediated inflammatory disease is GVHD, e.g., acute GVHD or chronic GVHD.

Aspects of the application provide anti-IL-13 antibodies and methods of using the same in treating IL-13-mediated diseases (e.g., allergic disease or other inflammatory diseases).

A compound represented by general formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, and a use thereof in treating diseases such as tumors, immunological diseases, and inflammatory diseases, as well as a pharmaceutical preparation and a pharmaceutical composition of the compound, and a use thereof.

Described herein are LAG3 specific single domain antibodies and binding molecules comprising such single domain antibodies, as well as nucleic acids encoding the same. Also provided are nucleic acids (e.g., mRNA) encoding such single domain antibodies and binding molecules and delivery vehicles (e.g., lipid nanoparticles) formulated with said nucleic acids. The disclosure also features methods of using such antibodies, binding molecules, nucleic acids, and delivery vehicles formulated with said nucleic acids to treat various diseases such as inflammatory diseases, T cell driven autoimmune diseases, and cancer (e.g., solid tumors or hematological malignancies).

The present invention relates to the use of beta-hydroxy-beta-methylbutyric acid (HMB) or a pharmaceutically acceptable salt thereof as an inhibitor of Gasdermin D (GSDMD) in the manufacture of a medicament for the treatment of pyroptosis. HMB modulates pyroptosis in macrophages by blocking palmitoylation of GSDMD and has the potential to be a novel therapeutic agent for the treatment of inflammatory diseases driven by pyroptosis disorders.

The present disclosure provides methods for treating an inflammatory disease or disorder, wherein the inflammatory disease or disorder is a metabolic disease or disorder, comprising administration of a GLP-1 receptor agonist (e.g., semaglutide, exendin-4), and an IL-2 protein (e.g., aldesleukin) to a subject. Also presented herein are compositions for use with the methods disclosed herein and kits for administering a GLP-1 receptor agonist (e.g., semaglutide, exendin- 4), and an IL-2 protein (e.g., aldesleukin).

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP and IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or IL-13.

The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

Described are synthetic compounds having anti-inflammatory properties and optionally analgesic properties. These compounds are derivatives of FDA-approved anti-inflammatory, such as ibuprofen and indomethacin, and can be formed using reactions under microwave irradiation. Generally, the compounds contains a moiety of the parent drug, a triazolyl heterocycle, and a substituted or unsubstituted aryl group. In some forms, the compounds show anti-inflammatory properties and optionally analgesic properties with similar or higher efficiencies compared with their respective parent drugs, with additional advantages including no or reduced adverse effects (e.g., without ulcerogenic liability in the gastric) and / or selective inhibition of COX-2 over COX-1. Pharmaceutical compositions suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating an inflammatory disease or disorder in a subject are also disclosed.

Disclosed are bispecific compounds (degraders) that target ERK5 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat cancer and inflammatory diseases.

Disclosed herein are methods of treating autoimmune, allergic, and / or inflammatory diseases in a subject in need thereof, comprising administering a therapeutic agent comprising one or more antigen-binding sites on a cell involved in the autoimmune, allergic, and / or inflammatory diseases and depleting the cell.

Disclosed herein, in on aspect, is a method of treating an immune or inflammatory disease, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD20 and CD3, thereby treating the immune or inflammatory disease.

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The present invention relates to a DcR3 variant, DNA encoding the DcR3 variant, a vector containing the DNA, a transformant obtained by introducing the vector, a method for producing a variant using the transformant, and a prophylactic or therapeutic agent for an autoimmune disease, an inflammatory disease or an allergic disease comprising the variant as an active ingredient. The present invention relates to a DcR3 variant having binding activity (preferably neutralizing activity) against a ligand of DcR3 while showing reduced production of aggregates and / or improved in vivo kinetics compared to wild-type DcR3 when prepared with a mammalian-derived cell as a host, and provides a DcR3 variant comprising a portion of DcR3 and a portion of a TNF superfamily molecule.

The application discloses a carbonyl heterocyclic compound and application thereof. The application provides a carbonyl heterocyclic compound as shown in formula II or a pharmaceutically acceptable salt thereof; the compound can be used as a compound with a targeted lipoamide synthetase C-like protein 2 path; and the compound can be used for treating various conditions, including infectious diseases, autoimmune diseases, diabetes and chronic inflammatory diseases.

The present application relates to heterocyclic compounds or pharmaceutically acceptable salts thereof as Janus kinase (JAK) inhibitors. In particular, the present application relates to a compound of general formula (I) or a pharmaceutically acceptable salt thereof. The present application also relates to a preparation method of the compound or the pharmaceutically acceptable salt thereof. The compound of the present application can be used for treating and / or preventing JAK-mediated related diseases, particularly inflammatory diseases, autoimmune diseases and cancers. In the general formula (I), each substituent is the same as defined in the specification.

The present application relates to a compound of formula X having PDE4B inhibitory activity, a pharmaceutical composition thereof, and a use. The compound of formula X may be used for PDE4-related diseases and conditions, such as respiratory inflammatory diseases, inflammatory bowel diseases, arthritis, skin inflammatory diseases, eye inflammatory diseases, and peripheral or central nervous system diseases or cancers.

The present disclosure relates, in part, to the selective inhibition of JUN N-terminal kinase (JNK1, JNK2, and / or JNK3; the present invention relates to compounds of formulae (I) and (II), which are also known as MAPK8, MAPK9 and / or MAPK10), pharmaceutical compositions thereof and methods of their use for treating, preventing and / or ameliorating one or more diseases and / or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and / or type 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting a disease and / or disorder in a subject with a suitable diagnostic method.

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and / or formulation thereof comprising the alpha and beta multi-subunits cytokines, such as IL-12 or IL-27, fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

The present disclosure provides a method of treating an autoimmune disease or inflammatory disease in an individual comprising administering to the individual a combination therapy. The combination therapy comprises a CD-2 binding molecule comprising a CD2-binding domain linked to an Fc domain and a composition comprising modified regulatory T (Treg) cells. The CD-2 binding molecule is administered first to precondition the individual for administration of the composition comprising the modified Treg cells.

The invention relates to a pharmaceutical formula of a Bruton's tyrosine kinase inhibitor. Described herein are pharmaceutical formulations of the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one. Also disclosed are methods of using Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

The present invention relates to compounds of formula (I) with STAT6 inhibitory activity for use in methods of treatment of inflammatory or allergic diseases, such as e.g. atopic dermatitis.

The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The invention discloses a compound and application thereof in preparation of a medicine for treating Alzheimer disease. The invention provides a method for constructing a disease animal model by using N-oleoyldopamine (OLDA) and application of the model in drug screening and animal experiment research. The animal model comprises at least one animal model of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases. According to the application, based on OLDA, it is found that the compound has new application in the aspects of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases, and based on OLDA, the compound which plays a certain role in treating the diseases is screened out.